Isotechnika Reports Full Year and Fourth Quarter 2012 Financial Results
April 03, 2013 18:05 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, April 3, 2013 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) (the "Company") has released its financial results for the year and quarter ended December 31, 2012.
Recent...
Isotechnika Merger With Aurinia to Create Leading Nephrology Company
February 05, 2013 12:30 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") and privately-held Aurinia Pharmaceuticals Inc. ("Aurinia") announced today the...
ILJIN Withdraws Damages Claims Against Isotechnika
January 15, 2013 16:15 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") is pleased to announce that ILJIN Life Sciences Co. Ltd. ("ILJIN") has formally...
Isotechnika Announces That Lux Biosciences' Phase 3 Uveitis Study Did Not Meet Primary Endpoint
December 27, 2012 07:50 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Dec. 27, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced today that the Phase 3 clinical study using voclosporin for the...
Isotechnika Pharma's NICAM Compounds Demonstrate Positive Anti-Hepatitis C Virus Activity in Secondary Level Testing at NIH-Funded Labs
December 06, 2012 15:00 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") is pleased to announce positive anti-hepatitis C virus ("HCV") results from the...
Isotechnika Receives Partial Award in ICC Arbitration With ILJIN
November 30, 2012 08:00 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Nov. 30, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced today that, further to its press release of November 14, 2012, a...
Isotechnika Cleared by FDA to Commence Phase 3 Voclosporin Trial
November 26, 2012 08:00 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Nov. 26, 2012 (GLOBE NEWSWIRE) -- Isotechnika Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced today that it has received permission from the U.S. Food and Drug...
Isotechnika Reports Third Quarter 2012 Financial Results
November 14, 2012 08:00 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Nov. 14, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) today announced financial results for the third quarter ended September 30, 2012.
The Company's financial and...
Isotechnika Pharma's NICAM Portfolio Demonstrates Positive Anti-Viral Activity Against Several Important Viruses
November 06, 2012 07:35 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") is pleased to announce positive results from the first round of screening of its...
Isotechnika Pharma Announces Close of Second Tranche of Private Placement of Units
October 31, 2012 08:00 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Oct. 31, 2012 (GLOBE NEWSWIRE) -- Further to its press release of October 16, 2012, Isotechnika Pharma Inc. (TSX:ISA) announced today that it has completed the second tranche of its...